Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Jul 20;37(21):1838-1840.
doi: 10.1200/JCO.19.00559. Epub 2019 Jun 7.

Exemestane Plus Ovarian Function Suppression Is the Best Adjuvant Treatment of Premenopausal Women With Endocrine-Responsive Breast Cancer at Higher Risk of Relapse and With HER2-Negative Tumors

Fabio Conforti  1 , Laura Pala  1
Affiliations
Comment

Exemestane Plus Ovarian Function Suppression Is the Best Adjuvant Treatment of Premenopausal Women With Endocrine-Responsive Breast Cancer at Higher Risk of Relapse and With HER2-Negative Tumors

Fabio Conforti et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Comment in

  • Reply to F. Conforti et al.
    Pan K, Bosserman L, Chlebowski RT. Pan K, et al. J Clin Oncol. 2019 Jul 20;37(21):1840-1841. doi: 10.1200/JCO.19.01133. Epub 2019 Jun 7. J Clin Oncol. 2019. PMID: 31173556 No abstract available.

Comment on

References

    1. Pan K, Bosserman LD, Chlebowski RT. Ovarian suppression in adjuvant endocrine therapy for premenopausal breast cancer. J Clin Oncol. 2019;37:858–861. - PubMed
    1. Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379:122–137. - PMC - PubMed
    1. Regan MM, Pagani O, Fleming GF, et al. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials. Breast. 2013;22:1094–1100. - PMC - PubMed
    1. Perrone F, De Laurentiis M, de Placido S, et al. The HOBOE-2 multicenter randomized phase III trial in premenopausal patients with hormone-receptor positive early breast cancer comparing triptorelin plus either tamoxifen or letrozole or letrozole + zoledronic acid. Ann Oncol. 2018;29 (abstr LBA14_PR)

LinkOut - more resources